Hormone Therapy in Breast and Prostate Cancer / Edition 1

Hormone Therapy in Breast and Prostate Cancer / Edition 1

by JORDAN V. CRAIG
ISBN-10:
1607614715
ISBN-13:
9781607614715
Pub. Date:
09/28/2009
Publisher:
Springer-Verlag New York, LLC
Select a Purchase Option (Softcover reprint of the original 1st ed. 2002)
  • purchase options
    $76.49 $89.99 Save 15% Current price is $76.49, Original price is $89.99. You Save 15%.
  • purchase options

Overview

Hormone Therapy in Breast and Prostate Cancer / Edition 1

Millions of people are now successfully using hormone antagonists for the treatment of endocrine-dependent cancers. In Hormone Therapy in Breast and Prostate Cancer, many of today's leading researchers and clinicians describe the principles underlying these targeted treatments, assess the actions of new and established agents, and illustrate the new applications of hormonal chemoprevention for breast cancer. Topics range from preclinical and clinical antiestrogens to the inhibition of estrogen synthesis and the effects of androgen withdrawal. A wide variety of proven and new agents are discussed-antiestrogens, including aromatase inhibitors (anastrozole, letrozole, and others), SERMs (tamoxifen, raloxifene, and others), and such antiandrogenic strategies as goserelin and bicalutamide. Unique in its synthesis, Hormone Therapy in Breast and Prostate Cancer offers medical and surgical oncologists, urologists, physicians, and clinical pharmacologists a sound basis for understanding targeted treatments of breast and prostate cancers, and provides a well-proven model for developing powerful new cancer therapeutics.

Product Details

ISBN-13: 9781607614715
Publisher: Springer-Verlag New York, LLC
Publication date: 09/28/2009
Series: Cancer Drug Discovery and Development Series
Edition description: Softcover reprint of the original 1st ed. 2002
Pages: 420
Product dimensions: 6.10(w) x 9.10(h) x 1.10(d)

Table of Contents

An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer
V. Craig Jordan and Barrington J. A. Furr

Part I. Preclinical Antiestrogens

Antiestrogens and the Cell Cycle
Colin K. W. Watts, Owen W. J. Prall, Jason S. Carroll, Nicholas R. C. Wilcken, Eileen M. Rogan, Elizabeth A. Musgrove, and Robert L. Sutherland

Drug Resistance to Antiestrogens
Ruth M. O'Regan, Anait S. Levenson, Gale M. England, Kathy A. Yao, Henry D. Muenzner, Hiroyuki Takei, and V. Craig Jordan

Mechanisms of Liver Carcinogenesis by Antiestrogens
David H. Phillips

The Effects of Triphenylethylene Antiestrogens on Parameters of Multistage Hepaarcinogenesis in the Rat
Yvonne P. Dragan and Henry C. Pitot

Preclinical Studies of Raloxifene and Related Compounds
Robin Fuchs-Young. Pure Antiestrogens, Alan E. Wakeling

Part II. Antiestrogens: Clinical

Tamoxifen for the Treatment of Breast Cancer
V. Craig Jordan

Clinical Utility of New Antiestrogens
Ruth M. O'Regan and William J. Gradishar

Breast Cancer Prevention with Antiestrogens
Monica Morrow and V. Craig Jordan

Part III. Inhibition of Estrogen Synthesis

Aromatase Inhibitors
Paul E. Goss and Caroline C. Reid

Clinical Utility of Aromatase Inhibitors
K. Shenton, Mitchell Dowsett, and Michael Dukes

LH-RH Agonists for the Treatment of Breast Cancer: Development and Current Status
Roger W. Blamey

Part IV. Androgen and Androgen Withdrawal

Molecular Action of Androgens
Shutsung Liao, Junichi Fukuchi, and Yung-Hsi Kao

Steroidal Antiandrogens
Fritz H. Schröder and Albert Radlmaier

Nonsteroidal Antiandrogens
Geert J. C. M. Kolvenbag and Barrington J. A. Furr

LH-RH Agonist Role in Prostate Cancer Management
Amir V. Kaisary

Part V. Perspective on Progress

Recent Progress in Breast Cancer Research
V. Craig Jordan and Barrington J. A. Furr

Customer Reviews

Most Helpful Customer Reviews

See All Customer Reviews